Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million Upfront

Details

for an upfront payment of $820 million and up to $500 million in contingent consideration. The acquisition includes ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, a rare genetic developmental and epileptic encephalopathy. The transaction is expected to close by the fourth quarter of 2026, subject to customary closing conditions. This acquisition strengthens Jazz's leadership in rare epilepsy and builds on its existing Epidiolex franchise.

Items reported

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.